VI Partners

Genkyotex, which develops selective NOX inhibitors, has closed $21 million in Series D funding. NeoMed Management, VI Partners and BioMedInvest led the round with participation from Edmond de Rothschild Investment Partners, Eclosion2 and Vesalius Biocapital Partners. In conjunction with the funding, Dr. Claudio Nessi of NeoMed has been added to Genkyotex’s board.

Sequana Medical has raised CHF 23 million ($26.2 million) in a Series C preferred share financing round led by Life Science Partners and co-led by NeoMed Management, VI Partners, BioMedInvest, Entrepreneurs Fund and Capricorn Venture Partners. The business is a Swiss medical device company.

Edimer Pharmaceuticals said Tuesday that it has closed $18 million in Series B financing. The lead investor was New Enterprise Associates. New investor Sanofi-Genzyme BioVentures and previous investors Third Rock Ventures and VI Partners also participated in the round. In addition to the news about funding, David Mott will join Edimer's board. Based in Cambridge, Mass., Edimer Pharmaceuticals is a biotech company.

Delenex Therapeutics AG completed its Series A funding round at CHF 13.5 million ($14 million). SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners led the financing. Delenex is a Zurich-Schlieren, Switzerland-based biotechnology company that develops therapeutic antibody fragments.

JenaValve, a German maker of aortic valves, has raised €19 million in Series B funding. Backers include GIMV, Atlas Venture, Edmond de Rothschild Investment Partners, Neomed Management, VI Partners and Sunstone Capital.

Activaero GmbH, a German developer of controlled breathing devices for inhaled therapeutic agents, has raised €10.7 million in Series A funding. BioMedPartners led the round, and was joined by VI Partners, Abalis Finance AG and Vesalius Biocapital. MedVenture Partners served as placement agent.

Endosense, a Geneva, Switzerland-based med-tech company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has raised $36 million in Series B funding. Edmond de Rothschild Investment Partners led the round, and was joined by Neomed, GIMV, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.

Oculis, a developer of ophthalmic treatments, has raised $57 million in Series C financing.

iOnctura B.V., a Swiss clinical stage biopharmaceutical company, has raised 15 million euros in Series A financing.

JenaValve Technology Inc, a maker of transcatheter aortic valve replacement systems, has named Dr. Vinny Podichetty as vice president of clinical affairs and Jeff Thiel as vice president of operations. The appointments became effective immediately. JenaValve’s backers include Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management, Omega Funds, RMM, Sunstone Capital, Valiance and VI Partners.

Nexthink, a provider of digital employee experience management software for enterprises, has secured $85 million in funding. Index Ventures led the round with participation from other investors that included Highland Europe, Forestay Capital, VI Partners, Auriga Partners, Galéo Capital and TOP Funds.

Xeltis, a European medical device company, has closed $52 million in Series C financing. The investors included Ysios Capital, Kurma Partners and VI Partners.

JenaValve Technology Inc, a maker of transcatheter aortic valve replacement systems, has named Pieter Van den Steen as chief commercial officer and general manager of the company's Munich office. Previously, Van den Steen worked at Boston Scientific. JenaValve's backers included Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management, Omega Funds, RMM, Sunstone Capital, Valiance and VI Partners.

Sequana Medical AG said Friday that it raised CHF 9 million (US$9.3 million) in a Series C extension round. Existing investors including NeoMed Management AS, VI Partners AG, Biomed Invest AG, Capricorn Health-tech Fund, Entrepreneurs Fund and Life Science Partners participated for a total of CHF 5.3M, with a further CHF 3.7M raised from new investors including Salus Partners SA and Quest for Growth NV. Sequana Medical, of Zurich, is a medical device company.

Swiss biotech company Kuros Biosurgery AG has raised CHF15M (approximately over $15.35 million) in funding. LifeCare Partners and LSP Life Sciences Partners led the round with participation from other investors that included Omega Funds, VI Partners (via Venture Incubator) and The Swiss Helvetia Fund Inc. In addition to the funding, Dr. Gerhard Ries, managing partner of LifeCare Partners, Dr. Jörg Neermann, a partner at LSP and Dominik Ellenrieder have been added to the Kuros board.